Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals

R. Clarke, D. Bennett, S. Parish, S. Lewington, M. Skeaff, S.J.P.M. Eussen, C. Lewerin, D.J. Stott, J. Armitage, G.J. Hankey, E. Lonn, J.D. Spence, P. Galan, L.C. de Groot, J. Halsey, A.D. Dangour, R. Collins, the B-Vitamin Treatment Trialists' Collaboration, F. Grodstein

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Elevated plasma homocysteine is a risk factor for Alzheimer disease, but the relevance of homocysteine lowering to slow the rate of cognitive aging is uncertain. Objective: The aim was to assess the effects of treatment with B vitamins compared with placebo, when administered for several years, on composite domains of cognitive function, global cognitive function, and cognitive aging. Design: A meta-analysis was conducted by using data combined from 11 large trials in 22,000 participants. Domain-based z scores (for memory, speed, and executive function and a domain-composite score for global cognitive function) were available before and after treatment (mean duration: 2.3 y) in the 4 cognitive-domain trials (1340 individuals); Mini-Mental State Examination (MMSE) type tests were available at the end of treatment (mean duration: 5 y) in the 7 global cognition trials (20,431 individuals). Results: The domain-composite and MMSE-type global cognitive function z scores both decreased with age (mean SE: 0.054 0.004 and 0.036 0.001/y, respectively). Allocation to B vitamins lowered homocysteine concentrations by 28% in the cognitive-domain trials but had no significant effects on the z score differences from baseline for individual domains or for global cognitive function (z score difference: 0.00; 95% CI: 0.05, 0.06). Likewise, allocation to B vitamins lowered homocysteine by 26% in the global cognition trials but also had no significant effect on end-treatment MMSE-type global cognitive function (z score difference: 0.01; 95% CI: 0.03, 0.02). Overall, the effect of a 25% reduction in homocysteine equated to 0.02 y (95% CI: 0.10, 0.13 y) of cognitive aging per year and excluded reductions of >1 mo per year of treatment. Conclusion: Homocysteine lowering by using B vitamins had no significant effect on individual cognitive domains or global cognitive function or on cognitive aging.
Original languageEnglish
Pages (from-to)657-666
Number of pages10
JournalAmerican Journal of Clinical Nutrition
Volume100
Issue number2
DOIs
Publication statusPublished - Aug 2014

Keywords

  • RANDOMIZED CONTROLLED-TRIAL
  • FOLIC-ACID SUPPLEMENTATION
  • PLACEBO-CONTROLLED TRIAL
  • ALZHEIMERS-DISEASE
  • OLDER-ADULTS
  • CARDIOVASCULAR-DISEASE
  • PLASMA HOMOCYSTEINE
  • STROKE PREVENTION
  • VASCULAR-DISEASE
  • DOUBLE-BLIND

Cite this

Clarke, R., Bennett, D., Parish, S., Lewington, S., Skeaff, M., Eussen, S. J. P. M., Lewerin, C., Stott, D. J., Armitage, J., Hankey, G. J., Lonn, E., Spence, J. D., Galan, P., de Groot, L. C., Halsey, J., Dangour, A. D., Collins, R., B-Vitamin Treatment Trialists' Collaboration, T., & Grodstein, F. (2014). Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. American Journal of Clinical Nutrition, 100(2), 657-666. https://doi.org/10.3945/ajcn.113.076349